Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lexeo Therapeutics, Inc. Common Stock
LXEOCurrent price
7.93 USD
-0.04 USD (-0.50%)
Last closed
7.9 USD
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
323 666 912 USD
Yield for 12 month
-21.09 %
1Y
3Y
5Y
10Y
15Y
LXEO
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. Address: 345 Park Avenue South, New York, NY, United States, 10010
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
22.43 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+654 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-1 843 000 USD
Last Year
-491 000 USD
Current Quarter
-496 000 USD
Last Quarter
-476 000 USD
Key Figures LXEO
1 year
3 years
5 years
10 years
EBITDA
-81 464 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-39.93 %
PEG Ratio
–
Return On Equity TTM
-74.83 %
Wall Street Target Price
22.43 USD
Revenue TTM
–
Book Value
4.99 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-12.53 USD
Diluted Eps TTM
-12.53 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics LXEO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LXEO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation LXEO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
416.3418
Price Sales TTM
–
Enterprise Value EBITDA
-6.0191
Price Book MRQ
1.9041
Financials LXEO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LXEO
For 52 weeks
7.86 USD
22.33 USD
50 Day MA
10.07 USD
Shares Short Prior Month
2 073 094
200 Day MA
13.51 USD
Short Ratio
5.46
Shares Short
2 058 541
Short Percent
6.97 %
BeatStart